The use of low molecular weight protamine chemical chimera to enhance monomeric insulin intestinal absorption

Biomaterials

Volumn 34, Issue 31, 2013, Pages 7733-7743

  He, Huining ^a,b   Sheng, Jianyong ^c   David, Allan E ^d   Kwon, Young Min ^e   Zhang, Jian ^f   Huang, Yongzhuo ^c,g   Wang, Jianxin ^c   Yang, Victor C ^a,f,h  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b TIANJIN UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

^d AUBURN UNIVERSITY   (United States)

^e NOVA SOUTHEASTERN UNIVERSITY   (United States)

^f UNIVERSITY OF MICHIGAN   (United States)

^g SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^h Seoul National University   (South Korea)

Author keywords

Cell penetrating peptide; Insulin; Intestinal absorption; Low molecular weight protamine; Monomeric conjugation; Permeation enhancement

Indexed keywords

CELL-PENETRATING PEPTIDE; INTESTINAL ABSORPTION; LOW MOLECULAR WEIGHT PROTAMINES; MONOMERIC CONJUGATION; PERMEATION ENHANCEMENT;

BIOCHEMISTRY; CELL CULTURE; CELL MEMBRANES; MOLECULAR WEIGHT; PEPTIDES;

INSULIN;

INSULIN; MACROGOL; MONOMER; PEPTIDE; PROTAMINE; SUCCIMER DERIVATIVE; SUCCINIMIDYL [(N MALEIMIDOPROPIONAMIDO) POLYETHYLENEGLYCOL] ESTER; UNCLASSIFIED DRUG;

ABSORPTION; ANIMAL EXPERIMENT; ARTICLE; BIOAVAILABILITY; CELL CULTURE; CHIMERA; CONJUGATION; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; HUMAN; HUMAN CELL; INTESTINE ABSORPTION; LIGHT; MASS SPECTROMETRY; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; RAT; RELIABILITY; TIME OF FLIGHT MASS SPECTROMETRY;

RATTUS;

EID: 84880958999     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.06.047     Document Type: Article

References (42)

1. Gerstein H.C., Miller M.E., Byington R.P., Goff D.C., Bigger J.T., Buse J.B., et al. Effects of intensive glucose lowering in type 2 diabetes. New Engl J Med 2008, 358:2545-2559.
2. Iyer H., Khedkar A., Verma M. Oral insulin - a review of current status. Diabetes Obes Metab 2010, 12:179-185.
3. Chen M.C., Sonaje K., Chen K.J., Sung H.W. Areview of the prospects for polymeric nanoparticle platforms in oral insulin delivery. Biomaterials 2011, 32:9826-9838.
4. Khafagy el S., Morishita M., Onuki Y., Takayama K. Current challenges in non-invasive insulin delivery systems: a comparative review. Adv Drug Deliver Rev 2007, 59:1521-1546.
5. Lin Y.H., Sonaje K., Lin K.M., Juang J.H., Mi F.L., Yang H.W., et al. Multi-ion-crosslinked nanoparticles with pH-responsive characteristics for oral delivery of protein drugs. JControl Release 2008, 132:141-149.
6. Woitiski C.B., Veiga F., Ribeiro A., Neufeld R. Design for optimization of nanoparticles integrating biomaterials for orally dosed insulin. Eur J Pharm Biopharm 2009, 73:25-33.
7. Yin L., Ding J., Zhang J., He C., Tang C., Yin C. Polymer integrity related absorption mechanism of superporous hydrogel containing interpenetrating polymer networks for oral delivery of insulin. Biomaterials 2010, 31:3347-3356.
8. Sonaje K., Chen Y.J., Chen H.L., Wey S.P., Juang J.H., Nguyen H.N., et al. Enteric-coated capsules filled with freeze-dried chitosan/poly(gamma-glutamic acid) nanoparticles for oral insulin delivery. Biomaterials 2010, 31:3384-3394.
9. Su F.Y., Lin K.J., Sonaje K., Wey S.P., Yen T.C., Ho Y.C., et al. Protease inhibition and absorption enhancement by functional nanoparticles for effective oral insulin delivery. Biomaterials 2012, 33:2801-2811.
10. Chang L.C., Lee H.F., Yang Z., Yang V.C. Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (I): preparation and characterization. AAPS PHARMSCI 2001, 3:7-14.
11. Chang L.C., Liang J.F., Lee H.F., Lee L.M., Yang V.C. Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (II): invitro evaluation of efficacy and toxicity. AAPS PHARMSCI 2001, 3:15-23.
12. Chang L., Wrobleski S., Wakefield T., Yang V. Low molecular weight protamine as nontoxic heparin/low molecular weight heparin antidote (III): Preliminary invivo evaluation of efficacy and toxicity using a canine model. AAPS PHARMSCI 2001, 3:24-31.
13. Schwarze Steven R., Ho A., Vocero-Akbani A., Dowdy S.F. Invivo protein transduction: delivery of a biologically active protein into the mouse. Science 1999, 285:1569-1572.
14. Schwarze S.R., Dowdy S.F. Invivo protein transduction: intracellular delivery of biologically active proteins, compounds and DNA. Trends Pharmacol Sci 2000, 21:45-48.
15. Park Y.J., Chang L.-C., Liang J.F., Moon C., Chung C.-P., Yang V.C. Nontoxic membrane translocation peptide from protamine, LMWP, for enhanced intracellular protein delivery - invitro and invivo study. FASEB J 2005, 19:1555.
16. Xia H., Gao X., Gu G., Liu Z., Zeng N., Hu Q., et al. Low molecular weight protamine-functionalized nanoparticles for drug delivery to the brain after intranasal administration. Biomaterials 2011, 32:9888-9898.
17. Liang J.F., Zhen L., Chang L.-C., Yang V.C. Aless toxic heparin antagonist- low molecular weight protamine. Biochemistry-Moscow+ 2003, 68:116-120.
18. Tsui B., Singh V.K., Liang J.F., Yang V.C. Reduced reactivity towards anti-protamine antibodies of a LMWP analogue. Thromb Res 2003, 101:417-420.
19. Carlsson J., Drevin H., Axen R. Protein thiolation and reversible protein-protein conjugation. N-succinimidyl 3-(2-pyridyldithio)propionate, a new heterobifunctional reagent. Biochem J 1978, 173:723-737.
20. Xia C.Q., Wang J., Shen W-C. Hypoglycemic effect of insulin-transferrin conjugate in streptozotocin-induced diabetic rats. JPharmacol Exp Ther 2000, 295:594-600.
21. Kavimandan N.J., Losi E., Wilson J.J., Brodbelt J.S., Peppas N.A. Synthesis and characterization of insulin-transferrin conjugation. Bioconjug Chem 2006, 17:1376-1384.
22. Morishita M., Kamei N., Ehara J., Isowa K., Takayama K. Anovel approach using functional peptides for efficient intestinal absorption of insulin. JControl Release 2007, 118:177-184.
23. Choi Y.S., Lee J.Y., Suh J.S., Kwon Y.M., Lee S.J., Chung J.K., et al. The systemic delivery of siRNAs by a cell penetrating peptide, low molecular weight protamine. Biomaterials 2010, 31:1429-1443.
24. Park Y.J., Liang J.F., Ko K.S., Kim S.W., Yang V.C. Low molecular weight protamine as an efficient and nontoxic gene carrier: invitro study. JGene Med 2003, 5:700-711.
25. Ignatovich I.A., Dizhe E.B., Pavlotskaya A.V., Akifiev B.N., Burov S.V., Orlov S.V., et al. Complexes of plasmid DNA with basic domain 47-57 of the HIV-1 Tat protein are transferred to mammalian cells by endocytosis-mediated pathways. JBiol Chem 2003, 278:42625-42636.
26. Simeoni F., Morris M.C., Heitz F., Divita G. Insight into the mechanism of the peptide-based gene delivery system MPG: implications for delivery of siRNA into mammalian cells. Nucleic Acids Res 2003, 31:2717-2724.
27. Sandgren S., Cheng F., Belting M. Nuclear targeting of macromolecular polyanions by an HIV-Tat derived peptide. Role for cell-surface proteoglycans. JBiol Chem 2002, 277:38877-38883.
28. Rudolph C., Plank C., Lausier J., Schillinger U., Muller R.H., Rosenecker J. Oligomers of the arginine-rich motif of the HIV-1 TAT protein are capable of transferring plasmid DNA into cells. JBiol Chem 2003, 278:11411-11418.
29. Unnamalai N., Kang B.G., Lee W.S. Cationic oligopeptide-mediated delivery of dsRNA for post-transcriptional gene silencing in plant cells. FEBS Lett 2004, 566:307-310.
30. Meade B.R., Dowdy S.F. Exogenous siRNA delivery using peptide transduction domains/cell penetrating peptides. Adv Drug Deliver Rev 2007, 59:134-140.
31. Meade B.R., Dowdy S.F. Enhancing the cellular uptake of siRNA duplexes following noncovalent packaging with protein transduction domain peptides. Adv Drug Deliver Rev 2008, 60:530-536.
32. Kamei N., Morishita M., Eda Y., Ida N., Nishio R., Takayama K. Usefulness of cell-penetrating peptides to improve intestinal insulin absorption. JControl Release 2008, 132:21-25.
33. Veronese F.M., Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today 2005, 10:1451-1458.
34. Uchio T., Baudyš M., Liu F., Song S.C., Kim S.W. Site-specific insulin conjugates with enhanced stability and extended action profile. Adv Drug Deliver Rev 1999, 35:289-306.
35. Hinds K.D., Kim S.W. Effects of PEG conjugation on insulin properties. Adv Drug Deliver Rev 2002, 54:505-530.
36. Lindsay D.G., Shall S. The acetylation of insulin. Biochem J 1971, 121:737-745.
37. Zheng C., Ma G., Su Z. Native PAGE eliminates the problem of PEG-SDS interaction in SDS-PAGE and provides an alternative to HPLC in characterization of protein PEGylation. Electrophoresis 2007, 28:2801-2807.
38. Artursson P., Karlsson J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Bioph Res Co 1991, 175:880-885.
39. Chong S., Dando S.A., Soucek K.M., Morrison R.A. Invitro permeability through Caco-2 cells is not quantitatively predictive of invivo absorption for peptide-like drugs absorbed via the dipeptide transporter system. Pharm Res 1996, 13:120-123.
40. Khafagy el S., Morishita M., Kamei N., Eda Y., Ikeno Y., Takayama K. Efficiency of cell-penetrating peptides on the nasal and intestinal absorption of therapeutic peptides and proteins. Int J Pharmaceut 2009, 381:49-55.
41. Chiu Y.L., Ali A., Chu C.Y., Cao H., Rana T.M. Visualizing a correlation between siRNA localization, cellular uptake, and RNAi in living cells. Chem Biol 2004, 11:1165-1175.
42. Turner J.J., Jones S., Fabani M.M., Ivanova G., Arzumanov A.A., Gait M.J. RNA targeting with peptide conjugates of oligonucleotides, siRNA and PNA. Blood Cell Mol Dis 2007, 38:1-7.